Julius Popp

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

90 publications

Sous presse | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2004 | 1998 |
Association between sleep characteristics and cognitive impairment in the general population: the Hypnolaus/Psycholaus Study
Haba-Rubio J Marti-Soler H Tobback N Andries D Marques-Vidal P Waeber G Vollenweider P von Gunten A Preisig M Castelao E Tafti M Heinzer R Popp J. Neurology. Peer-reviewed.
Life events do not explain the link between cortisol and poorer cognition in non-demented subjects: a population-based study
Ouanes S., Castelao E., Von Gunten A., Preisig M., Popp J. Neurobiology of Aging.
Personality, Cortisol, and Cognition in Non-Demented Subjects: A Population-Based Study
Ouanes Sami, Castelao Enrique, von Gunten Armin, Marques-Vidal Pedro, Preisig Martin, Popp Julius Front. Aging Neurosci.. Peer-reviewed.
Recommendations for prevention, diagnostic and therapy of delirium in the elderly.
Savaskan E, Baumgartner M, Georgescu D, Hafner M, Hasemann W. Kressig RE, Popp J, Rohrbach E, Schmid R, Verloo H. Praxis (Bern 1994). Peer-reviewed.
Inflammatory biomarkers in Alzheimer's disease plasma.
Morgan A.R., Touchard S., Leckey C., O'Hagan C., Nevado-Holgado A.J., NIMA Consortium, Barkhof F., Bertram L., Blin O., Bos I. et al., 2019/06. Alzheimer's & dementia, 15 (6) pp. 776-787. Peer-reviewed.
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
Kim M., Snowden S., Suvitaival T., Ali A., Merkler D.J., Ahmad T., Westwood S., Baird A., Proitsi P., Nevado-Holgado A. et al., 2019/06. Alzheimer's & dementia, 15 (6) pp. 817-827. Peer-reviewed.
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I., Vos S., Verhey F., Scheltens P., Teunissen C., Engelborghs S., Sleegers K., Frisoni G., Blin O., Richardson J.C. et al., 2019/05. Alzheimer's & dementia, 15 (5) pp. 644-654. Peer-reviewed.
Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults.
Dayon L., Cominetti O., Wojcik J., Galindo A.N., Oikonomidi A., Henry H., Migliavacca E., Kussmann M., Bowman G.L., Popp J., 2019/03/01. Journal of proteome research, 18 (3) pp. 1162-1174. Peer-reviewed.
High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature.
Ouanes S., Popp J., 2019. Frontiers in aging neuroscience, 11 p. 43. Peer-reviewed.
A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: Exploring gender-associated variation in a cohort of elderly cognitively healthy subjects.
Gallart-Ayala H., Konz I., Mehl F., Teav T., Oikonomidi A., Peyratout G., van der Velpen V., Popp J., Ivanisevic J., 2018/12/11. Analytica chimica acta, 1037 pp. 327-337. Peer-reviewed.
Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults.
Bowman G.L., Dayon L., Kirkland R., Wojcik J., Peyratout G., Severin I.C., Henry H., Oikonomidi A., Migliavacca E., Bacher M. et al., 2018/12. Alzheimer's & dementia, 14 (12) pp. 1640-1650. Peer-reviewed.
LC-HRMS data as a result of untargeted metabolomic profiling of human cerebrospinal fluid.
Mehl F., Gallart-Ayala H., Konz I., Teav T., Oikonomidi A., Peyratout G., van der Velpen V., Popp J., Ivanisevic J., 2018/12. Data in brief, 21 pp. 1358-1362. Peer-reviewed.
The Effects of Hand Massage on Stress and Agitation Among People with Dementia in a Hospital Setting: A Pilot Study.
Schaub C., Von Gunten A., Morin D., Wild P., Gomez P., Popp J., 2018/12. Applied psychophysiology and biofeedback, 43 (4) pp. 319-332. Peer-reviewed.
MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
Ten Kate M., Redolfi A., Peira E., Bos I., Vos S.J., Vandenberghe R., Gabel S., Schaeverbeke J., Scheltens P., Blin O. et al., 2018/09/27. Alzheimer's research & therapy, 10 (1) p. 100. Peer-reviewed.
Do diurnal cortisol levels mediate the association between sleep disturbances and cognitive impairment?
Haba-Rubio J., Ouanes S., Franc Y., Marques-Vidal P., Waeber G., Vollenweider P., von Gunten A., Preisig M., Kuehner C., Castelao E. et al., 2018/09. Neurobiology of aging, 69 pp. 65-67. Peer-reviewed.
Alzheimer disease pathology and the cerebrospinal fluid proteome.
Dayon L., Núñez Galindo A., Wojcik J., Cominetti O., Corthésy J., Oikonomidi A., Henry H., Kussmann M., Migliavacca E., Severin I. et al., 2018/07/18. Alzheimer's research & therapy, 10 (1) p. 66. Peer-reviewed.
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
Bos I., Vos S., Vandenberghe R., Scheltens P., Engelborghs S., Frisoni G., Molinuevo J.L., Wallin A., Lleó A., Popp J. et al., 2018/07/06. Alzheimer's research & therapy, 10 (1) p. 64. Peer-reviewed.
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.
Mattsson N., Groot C., Jansen W.J., Landau S.M., Villemagne V.L., Engelborghs S., Mintun M.M., Lleo A., Molinuevo J.L., Jagust W.J. et al., 2018/07. Alzheimer's & dementia, 14 (7) pp. 913-924. Peer-reviewed.
Die Empfehlungen der Swiss Memory Clinics für die Diagnostik der Demenzerkrankungen [Recommendations of Swiss Memory Clinics for the Diagnosis of Dementia]
Bürge M., Bieri G., Brühlmeier M., Colombo F., Demonet J.F., Felbecker A., Georgescu D., Gietl A., Brioschi Guevara A., Jüngling F. et al., 2018/04. Praxis, 107 (8) pp. 435-451. Peer-reviewed.
Etat confusionnel aigu de la personne âgée
von Gunten Armin, Baumgartner Markus, Georgescu Dan, Hafner Martina, Hasemann Wolfgang, Kressig Reto W., Popp Julius, Rohrbach Erich, Schmid Ruth, Verloo Henk et al., 2018/03/21. Forum Médical Suisse ‒ Swiss Medical Forum, 18 (12) pp. 277-284.
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
Jansen W.J., Ossenkoppele R., Tijms B.M., Fagan A.M., Hansson O., Klunk W.E., van der Flier W.M., Villemagne V.L., Frisoni G.B., Fleisher A.S. et al., 2018/01/01. JAMA psychiatry, 75 (1) pp. 84-95. Peer-reviewed.
Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J., Gholamrezaee M., Henry H., von Gunten A., Popp J., 2017/12/15. Experimental gerontology, 100 pp. 45-53. Peer-reviewed.
Response to a letter to the editor: sleep disturbance as a stressor event in elderly's life.
Ouanes S., Haba-Rubio J., Popp J., 2017/12. Neurobiology of aging, 60 p. 204. Peer-reviewed.
Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology.
Tautvydaitė D., Antonietti J.P., Henry H., von Gunten A., Popp J., 2017/07. Journal of psychiatric research, 90 pp. 12-20. Peer-reviewed.
One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond.
Dayon L., Guiraud S.P., Corthésy J., Da Silva L., Migliavacca E., Tautvydaitė D., Oikonomidi A., Moullet B., Henry H., Métairon S. et al., 2017/06/17. Alzheimer's research & therapy, 9 (1) p. 43. Peer-reviewed.
ICP-MS/MS-Based Ionomics: A Validated Methodology to Investigate the Biological Variability of the Human Ionome.
Konz T., Migliavacca E., Dayon L., Bowman G., Oikonomidi A., Popp J., Rezzi S., 2017/05/05. Journal of proteome research, 16 (5) pp. 2080-2090. Peer-reviewed.
Macrophage migration inhibitory factor is associated with biomarkers of Alzheimer's disease pathology and predicts cognitive decline in MCI and mild dementi
Popp J., Oikonomidi A., Tautvydaite D., Gholamrezaee M., Henry H., Bacher M., 2017/05/01., 13th International Conference on Alzheimer's and Parkinson's Diseases, AD/PD 2017 p. 394 dans Neurodegenerative Diseases.
Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J., Oikonomidi A., Tautvydaitė D., Dayon L., Bacher M., Migliavacca E., Henry H., Kirkland R., Severin I., Wojcik J. et al., 2017/04. Brain, behavior, and immunity, 62 pp. 203-211. Peer-reviewed.
Life events, salivary cortisol, and cognitive performance in nondemented subjects: a population-based study.
Ouanes S., Castelao E., Gebreab S., von Gunten A., Preisig M., Popp J., 2017/03. Neurobiology of aging, 51 pp. 1-8. Peer-reviewed.
Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance.
Tautvydaitė D., Kukreja D., Antonietti J.P., Henry H., von Gunten A., Popp J., 2017/02/02. Alzheimer's research & therapy, 9 (1) p. 6. Peer-reviewed.
Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study.
Haba-Rubio J., Marti-Soler H., Tobback N., Andries D., Marques-Vidal P., Waeber G., Vollenweider P., von Gunten A., Preisig M., Castelao E. et al., 2017/01/31. Neurology, 88 (5) pp. 463-469. Peer-reviewed.
Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
Oikonomidi A., Tautvydaitė D., Gholamrezaee M.M., Henry H., Bacher M., Popp J., 2017. Journal of Alzheimer's disease, 60 (1) pp. 273-281. Peer-reviewed.
Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease
Zufferey Valérie, Donati Alessia, Popp Julius, Meuli Reto, Rossier Jérôme, Frackowiak Richard, Draganski Bogdan, von Gunten Armin, Kherif Ferath, 2017. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 7 pp. 107-114. Peer-reviewed.
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.
Lewczuk P., Lelental N., Lachmann I., Holzer M., Flach K., Brandner S., Engelborghs S., Teunissen C.E., Zetterberg H., Molinuevo J.L. et al., 2017. Journal of Alzheimer's disease, 55 (1) pp. 159-170. Peer-reviewed.
Personality, Cortisol, and Cognition in Non-demented Elderly Subjects: Results from a Population-Based Study.
Ouanes S., Castelao E., von Gunten A., Vidal P.M., Preisig M., Popp J., 2017. Frontiers in aging neuroscience, 9 p. 63. Peer-reviewed.
Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L., Wojcik J., Núñez Galindo A., Corthésy J., Cominetti O., Oikonomidi A., Henry H., Migliavacca E., Bowman G.L., Popp J., 2017. Journal of Alzheimer's disease, 60 (4) pp. 1641-1652. Peer-reviewed.
Empfehlungen zur Prävention, Diagnostik und Therapie des Delirs im Alter
Savaskan Egemen, Baumgartner Markus, Georgescu Dan, Hafner Martina, Hasemann Wolfgang, Kressig Reto W., Popp Julius, Rohrbach Erich, Schmid Ruth, Verloo Henk, 2016/08. PRAXIS, 105 (16) pp. 941-952. Peer-reviewed.
L'agitation chez les personnes atteintes de démence : Examen de la portée des connaissances et mise en perspective du phénomène selon la théorie du confort et le concept de l'attachement
Schaub Corinne, Morin Diane, Popp Julius, Von Gunten Armin, 2016/06. Recherche en soins infirmiers pp. 68-83. Peer-reviewed.
Les biomarqueurs du liquide céphalo-rachidien dans la maladie d'Alzheimer en pratique clinique courante [Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].
Magnin E., Popp J., 2016/04. Revue Medicale Suisse, 12 (515) pp. 791-794. Peer-reviewed.
Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta.
Oikonomidi A., Lewczuk P., Kornhuber J., Smulders Y., Linnebank M., Semmler A., Popp J., 2016. Journal of Neurochemistry, 139 (2) pp. 324-332. Peer-reviewed.
Delirium in the elderly: Current problems with increasing geriatric age.
Kukreja D., Günther U., Popp J., 2015/12. The Indian journal of medical research, 142 (6) pp. 655-662. Peer-reviewed.
Behavioral and psychological symptoms and cognitive decline in patients with amnestic MCI and mild AD: a two-year follow-up study.
Pocnet C., Antonietti J.P., Donati A., Popp J., Rossier J., von Gunten A., 2015. International Psychogeriatrics / Ipa, 27 (8) pp. 1379-1389. Peer-reviewed.
Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J., Wolfsgruber S., Heuser I., Peters O., Hüll M., Schröder J., Möller H.J., Lewczuk P., Schneider A., Jahn H. et al., 2015. Neurobiology of Aging, 36 (2) pp. 601-607. Peer-reviewed.
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
Ewers M., Mattsson N., Minthon L., Molinuevo J.L., Antonell A., Popp J., Jessen F., Herukka S.K., Soininen H., Maetzler W. et al., 2015. Alzheimer's and Dementia, 11 (11) pp. 1306-1315. Peer-reviewed.
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R., Visser P.J., Amyloid Biomarker Study Group, Aalten P., Aalten P. et al., 2015. Jama, 313 (19) pp. 1924-1938. Peer-reviewed.
Empfehlungen zur Diagnostik und Therapie der behavioralen und psychologischen Symptome der Demenz (BPSD) [Recommendations for diagnosis and therapy of behavioral and psychological symptoms in dementia (BPSD)].
Savaskan E., Bopp-Kistler I., Buerge M., Fischlin R., Georgescu D., Giardini U., Hatzinger M., Hemmeter U., Justiniano I., Kressig R.W. et al., 2014. Praxis, 103 (3) pp. 135-148. Peer-reviewed.
Subjective cognitive decline in patients with mild cognitive impairment and healthy older adults: Association with personality traits.
Studer J., Donati A., Popp J., von Gunten A., 2014. Geriatrics and Gerontology International, 14 (3) pp. 589-595. Peer-reviewed.
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Ramirez A., van der Flier W.M., Herold C., Ramonet D., Heilmann S., Lewczuk P., Popp J., Lacour A., Drichel D., Louwersheimer E. et al., 2014. Human Molecular Genetics, 23 (24) pp. 6644-6658. Peer-reviewed.
Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease.
Popp J., Meichsner S., Kölsch H., Lewczuk P., Maier W., Kornhuber J., Jessen F., Lütjohann D., 2013. Biochemical Pharmacology, 86 (1) pp. 37-42. Peer-reviewed.
Delirium and cognitive decline: more than a coincidence.
Popp J., 2013. Current Opinion in Neurology, 26 (6) pp. 634-639. Peer-reviewed.
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.
Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Förster S., Winter Y., Bach J.P., Popp J., Alferink J. et al., 2013. Lancet Neurology, 12 (3) pp. 233-243. Peer-reviewed.
Predisposing and precipitating factors of delirium after cardiac surgery: a prospective observational cohort study.
Guenther U., Theuerkauf N., Frommann I., Brimmers K., Malik R., Stori S., Scheidemann M., Putensen C., Popp J., 2013. Annals of Surgery, 257 (6) pp. 1160-1167. Peer-reviewed.
The evolution of personality in patients with mild cognitive impairment.
Donati A., Studer J., Petrillo S., Pocnet C., Popp J., Rossier J., von Gunten A., 2013. Dementia and Geriatric Cognitive Disorders, 36 (5-6) pp. 329-339. Peer-reviewed.
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
Wagner M., Wolf S., Reischies F.M., Daerr M., Wolfsgruber S., Jessen F., Popp J., Maier W., Hüll M., Frölich L. et al., 2012. Neurology, 78 (6) pp. 379-386. Peer-reviewed.
Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
Lewczuk P., Popp J., Lelental N., Kölsch H., Maier W., Kornhuber J., Jessen F., 2012. Journal of Alzheimer's Disease, 28 (1) pp. 119-125. Peer-reviewed.
Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease.
Popp J., Lewczuk P., Kölsch H., Meichsner S., Maier W., Kornhuber J., Jessen F., Lütjohann D., 2012. Journal of Neurochemistry, 123 (2) pp. 310-316. Peer-reviewed.
Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients.
Rogacev K.S., Pinsdorf T., Weingärtner O., Gerhart M.K., Welzel E., van Bentum K., Popp J., Menzner A., Fliser D., Lütjohann D. et al., 2012. Clinical Journal of the American Society of Nephrology, 7 (6) pp. 943-948. Peer-reviewed.
Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid.
Smith D.E., Smulders Y.M., Blom H.J., Popp J., Jessen F., Semmler A., Farkas M., Linnebank M., 2012. Clinical Chemistry and Laboratory Medicine, 50 (9) pp. 1641-1647. Peer-reviewed.
Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease.
Noelker C., Schwake M., Balzer-Geldsetzer M., Bacher M., Popp J., Schlegel J., Eggert K., Oertel W.H., Klockgether T., Dodel R.C., 2012. Neuroscience Letters, 507 (1) pp. 10-15. Peer-reviewed.
Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease.
Arlt S., Schwedhelm E., Kölsch H., Jahn H., Linnebank M., Smulders Y., Jessen F., Böger R.H., Popp J., 2012. Journal of Alzheimer's Disease : Jad, 31 (4) pp. 751-758. Peer-reviewed.
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment.
Scheef L., Spottke A., Daerr M., Joe A., Striepens N., Kölsch H., Popp J., Daamen M., Gorris D., Heneka M.T. et al., 2012. Neurology, 79 (13) pp. 1332-1339. Peer-reviewed.
Implications of Objective vs Subjective Delirium Assessment in Surgical Intensive Care Patients.
Guenther U., Weykam J., Andorfer U., Theuerkauf N., Popp J., Ely E.W., Putensen C., 2012. American Journal of Critical Care : An Official Publication, American Association of Critical-care Nurses, 21 (1) pp. e12-e20. Peer-reviewed.
Prevention and treatment options for postoperative delirium in the elderly.
Popp J., Arlt S., 2012. Current Opinion In Psychiatry, 25 (6) pp. 515-521. Peer-reviewed.
Association of N-acetylaspartate and cerebrospinal fluid Aβ42 in dementia.
Jessen F., Lewczuk P., Gür O., Block W., Ende G., Frölich L., Hammen T., Arlt S., Kornhuber J., Kucinski T. et al., 2011. Journal of Alzheimer's Disease, 27 (2) pp. 393-399. Peer-reviewed.
Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume.
Striepens N., Scheef L., Wind A., Meiberth D., Popp J., Spottke A., Kölsch H., Wagner M., Jessen F., 2011. Psychological Medicine, 41 (9) pp. 1997-2006. Peer-reviewed.
Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
Popp J., Arlt S., 2011. Current Opinion In Psychiatry, 24 (6) pp. 556-561. Peer-reviewed.
The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease.
Vanmierlo T., Popp J., Kölsch H., Friedrichs S., Jessen F., Stoffel-Wagner B., Bertsch T., Hartmann T., Maier W., von Bergmann K. et al., 2011. Acta Psychiatrica Scandinavica, 124 (3) pp. 184-192. Peer-reviewed.
Alterations of cholesterol precursor levels in Alzheimer's disease.
Kölsch H., Heun R., Jessen F., Popp J., Hentschel F., Maier W., Lütjohann D., 2010. Biochimica et Biophysica Acta, 1801 (8) pp. 945-950. Peer-reviewed.
Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
Popp J., Lewczuk P., Frommann I., Kölsch H., Kornhuber J., Maier W., Jessen F., 2010. Journal of Alzheimer's Disease : Jad, 22 (2) pp. 459-468. Peer-reviewed.
S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease.
Linnebank M., Popp J., Smulders Y., Smith D., Semmler A., Farkas M., Kulic L., Cvetanovska G., Blom H., Stoffel-Wagner B. et al., 2010. Neuro-degenerative Diseases, 7 (6) pp. 373-378. Peer-reviewed.
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Lewczuk P., Kamrowski-Kruck H., Peters O., Heuser I., Jessen F., Popp J., Bürger K., Hampel H., Frölich L., Wolf S. et al., 2010. Molecular Psychiatry, 15 (2) pp. 138-145. Peer-reviewed.
The role of macrophage migration inhibitory factor in Alzheimer's disease.
Bacher M., Deuster O., Aljabari B., Egensperger R., Neff F., Jessen F., Popp J., Noelker C., Reese J.P., Al-Abed Y. et al., 2010. Molecular Medicine (cambridge, Mass.), 16 (3-4) pp. 116-121. Peer-reviewed.
Validity and reliability of the CAM-ICU Flowsheet to diagnose delirium in surgical ICU patients.
Guenther U., Popp J., Koecher L., Muders T., Wrigge H., Ely E.W., Putensen C., 2010. Journal of Critical Care, 25 (1) pp. 144-151. Peer-reviewed.
Volume loss of the medial temporal lobe structures in subjective memory impairment.
Striepens N., Scheef L., Wind A., Popp J., Spottke A., Cooper-Mahkorn D., Suliman H., Wagner M., Schild H.H., Jessen F., 2010. Dementia and Geriatric Cognitive Disorders, 29 (1) pp. 75-81. Peer-reviewed.
Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions.
Qureischie H., Heun R., Popp J., Jessen F., Maier W., Schmitz S., Hentschel F., Kelemen P., Kölsch H., 2009. Journal of Neural Transmission (vienna, Austria : 1996), 116 (4) pp. 467-472. Peer-reviewed.
CSF cortisol in Alzheimer's disease and mild cognitive impairment.
Popp J., Schaper K., Kölsch H., Cvetanovska G., Rommel F., Klingmüller D., Dodel R., Wüllner U., Jessen F., 2009. Neurobiology of Aging, 30 (3) pp. 498-500. Peer-reviewed.
CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.
Kölsch H., Lütjohann D., Jessen F., Popp J., Hentschel F., Kelemen P., Schmitz S., Maier W., Heun R., 2009. European Psychiatry : the Journal of the Association of European Psychiatrists, 24 (3) pp. 183-190. Peer-reviewed.
Deutsche Kurzversion: Confusion Assessment Method for Intensive Care Unit zur routine­mäßigen Kontrolle des Delirs auf Intensivstation = German short version of the Confusion Assessment Method for the Intensive Care Unit for routine delirium monitoring
Günther U., Muders T., Wrigge H., Popp J., Andorfer U., Putensen C., 2009. Anaesthesiologie und Intensivmedizin, 50 (10) pp. 592-600. Peer-reviewed.
Gene variations in GSTM3 are a risk factor for Alzheimer's disease.
Hong G.S., Heun R., Jessen F., Popp J., Hentschel F., Kelemen P., Schulz A., Maier W., Kölsch H., 2009. Neurobiology of Aging, 30 (5) pp. 691-696. Peer-reviewed.
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease.
Popp J., Lewczuk P., Linnebank M., Cvetanovska G., Smulders Y., Kölsch H., Frommann I., Kornhuber J., Maier W., Jessen F., 2009. Journal of Alzheimer's Disease, 18 (4) pp. 819-828. Peer-reviewed.
Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J., Bacher M., Kölsch H., Noelker C., Deuster O., Dodel R., Jessen F., 2009. Journal of Psychiatric Research, 43 (8) pp. 749-753. Peer-reviewed.
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.
Klafki H.W., Lewczuk P., Kamrowski-Kruck H., Maler J.M., Müller K., Peters O., Heuser I., Jessen F., Popp J., Frölich L. et al., 2009. Journal of Alzheimer's Disease : Jad, 18 (3) pp. 613-622. Peer-reviewed.
Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia.
Alexopoulos P., Günther F., Popp J., Jessen F., Peters O., Wolf S., Kneib T., Kurz A., Richter-Schmidinger T., Lewczuk P. et al., 2009. Journal of the American Geriatrics Society, 57 (4) pp. 737-739. Peer-reviewed.
RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism.
Kölsch H., Lütjohann D., Jessen F., Popp J., Hentschel F., Kelemen P., Friedrichs S., Maier T.A., Heun R., 2009. Journal of Cellular and Molecular Medicine, 13 (3) pp. 589-598. Peer-reviewed.
CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk.
Qureischie H., Heun R., Lütjohann D., Popp J., Jessen F., Ledschbor-Frahnert C., Thiele H., Maier W., Hentschel F., Kelemen P. et al., 2008. Brain Research, 1232 pp. 1-6. Peer-reviewed.
KIBRA gene variants are associated with episodic memory in healthy elderly.
Schaper K., Kolsch H., Popp J., Wagner M., Jessen F., 2008. Neurobiology of Aging, 29 (7) pp. 1123-1125. Peer-reviewed.
Ambulante Durchführung einer diagnostischen Lumbalpunktion in der Gedächtnissprechstunde. Häufigkeit und Risikofaktoren eines postpunktionellen Syndroms [Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic. Frequency and risk factors of post-lumbar puncture headache].
Popp J., Riad M., Freymann K., Jessen F., 2007. Der Nervenarzt, 78 (5) pp. 547-551. Peer-reviewed.
Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subject.
Popp J., Thal D.R., Lewczuk P., Wiltfang J., Jessen F., 2007. Journal of Neurology, 254 (7) pp. 970-971. Peer-reviewed.
Mechanical ventilation in ischemic stroke.
Milhaud D., Popp J., Thouvenot E., Heroum C., Bonafé A., 2004. Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association, 13 (4) pp. 183-188. Peer-reviewed.
Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor.
Bitzer M., Opitz H., Popp J., Morgalla M., Gruber A., Heiss E., Voigt K., 1998. Acta Neurochirurgica, 140 (4) pp. 333-340. Peer-reviewed.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University